The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Table of contents

 

Chemical Compound Review

Nimbium     benzenesulfonate; 5-[3-[(1R,2R)-1-[(3,4...

Synonyms: Nimbex, Cisatracurium, Nimbex (TN), CHEBI:3721, Nimbex Forte, ...
This record was replaced with 62887.
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of 3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoic acid 5-[3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl ester

 

High impact information on 3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoic acid 5-[3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl ester

 

Chemical compound and disease context of 3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoic acid 5-[3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl ester

 

Biological context of 3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoic acid 5-[3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl ester

 

Anatomical context of 3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoic acid 5-[3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl ester

 

Associations of 3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoic acid 5-[3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl ester with other chemical compounds

 

Gene context of 3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoic acid 5-[3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl ester

  • Cisatracurium infusion rates ranged from 6.3 to 10.5 microg/kg/min, with an average of 8.0 microg/kg/min [22].
  • After discontinuing cisatracurium administration, recovery to 70% TOF ratio averaged 68 +/- 13 min [23].
  • One-way ANOVA showed a statistically significant difference between the cisatracurium infusion rates before, during and after CPB: A T1/T0 of 15% could be achieved with a mean infusion rate of 1.1, 0.75 and 0.98 micrograms kg-1 min-1 before, during and after CPB, respectively [24].
  • The degradation products of cistracurium were identified by ESI positive-ion detection as Hofmann elimination and ester hydrolysis products of cisatracurium [25].
  • Response to cisatracurium in patient with Charcot-Marie-Tooth disease [26].
 

Analytical, diagnostic and therapeutic context of 3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoic acid 5-[3-[(1R,2R)-6,7-dimethoxy-2-methyl-1-veratryl-3,4-dihydro-1H-isoquinolin-2-yl]propanoyloxy]pentyl ester

References

  1. Clinical pharmacokinetics of cisatracurium besilate. Kisor, D.F., Schmith, V.D. Clinical pharmacokinetics. (1999) [Pubmed]
  2. Anaphylactic reaction after cisatracurium. Clendenen, S.R., Harper, J.V., Wharen, R.E., Guarderas, J.C. Anesthesiology (1997) [Pubmed]
  3. A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients. Newman, P.J., Quinn, A.C., Grounds, R.M., Hunter, J.M., Boyd, A.H., Eastwood, N.B., Pollard, B.J., Pearson, A.J., Harper, N.J., Beale, R.J., Sutjarittam, M., Elliot, J.M., Bion, J.F. Crit. Care Med. (1997) [Pubmed]
  4. Dose-response relationship and infusion requirement of cisatracurium besylate in infants and children during nitrous oxide-narcotic anesthesia. de Ruiter, J., Crawford, M.W. Anesthesiology (2001) [Pubmed]
  5. The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma. Welch, R.M., Brown, A., Ravitch, J., Dahl, R. Clin. Pharmacol. Ther. (1995) [Pubmed]
  6. Prospective use of population pharmacokinetics/pharmacodynamics in the development of cisatracurium. Schmith, V.D., Fiedler-Kelly, J., Phillips, L., Grasela, T.H. Pharm. Res. (1997) [Pubmed]
  7. Respiratory failure in tetanus: case report and review of a 25-year experience. Bunch, T.J., Thalji, M.K., Pellikka, P.A., Aksamit, T.R. Chest (2002) [Pubmed]
  8. Total intravenous anesthesia with remifentanil, propofol and cisatracurium in end-stage renal failure. Dahaba, A.A., von Klobucar, F., Rehak, P.H., List, W.F. Canadian journal of anaesthesia = Journal canadien d'anesthésie. (1999) [Pubmed]
  9. Persistent anaphylactic reaction after induction with thiopentone and cisatracurium. Briassoulis, G., Hatzis, T., Mammi, P., Alikatora, A. Paediatric anaesthesia. (2000) [Pubmed]
  10. Comparison of cisatracurium and vecuronium by infusion in neonates and small infants after congenital heart surgery. Reich, D.L., Hollinger, I., Harrington, D.J., Seiden, H.S., Chakravorti, S., Cook, D.R. Anesthesiology (2004) [Pubmed]
  11. Comparative clinical pharmacology of rocuronium, cisatracurium, and their combination. Naguib, M., Samarkandi, A.H., Ammar, A., Elfaqih, S.R., Al-Zahrani, S., Turkistani, A. Anesthesiology (1998) [Pubmed]
  12. Gastric emptying in mechanically ventilated critically ill patients: effect of neuromuscular blocking agent. Tamion, F., Hamelin, K., Duflo, A., Girault, C., Richard, J.C., Bonmarchand, G. Intensive care medicine. (2003) [Pubmed]
  13. The safety and efficacy of cisatracurium 0.15 mg.kg(-1) during nitrous oxide-opioid anaesthesia in infants and children. Taivainen, T., Meakin, G.H., Meretoja, O.A., Wirtavuori, K., Perkins, R.J., Murphy, A.K., Fisher, G.R., Waiter, M.R. Anaesthesia. (2000) [Pubmed]
  14. Cisatracurium, but not mivacurium, inhibits survival and axonal growth of neonatal and adult rat peripheral neurons in vitro. Lirk, P., Longato, S., Rieder, J., Klimaschewski, L. Neurosci. Lett. (2004) [Pubmed]
  15. Cisatracurium besilate. A review of its pharmacology and clinical potential in anaesthetic practice. Bryson, H.M., Faulds, D. Drugs (1997) [Pubmed]
  16. The influence of atracurium, cisatracurium, and mivacurium on the proliferation of two human cell lines in vitro. Amann, A., Rieder, J., Fleischer, M., Niedermüller, P., Hoffmann, G., Amberger, A., Marth, C., Nigrovic, V., Pühringer, F. Anesth. Analg. (2001) [Pubmed]
  17. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. Ebo, D.G., Bridts, C.H., Hagendorens, M.M., Mertens, C.H., De Clerck, L.S., Stevens, W.J. Allergy (2006) [Pubmed]
  18. The lumbar paravertebral region provides a novel site to assess neuromuscular block at the diaphragm. Hemmerling, T.M., Schmidt, J., Hanusa, C., Wolf, T., Jacobi, K.E. Canadian journal of anaesthesia = Journal canadien d'anesthésie. (2001) [Pubmed]
  19. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. Tran, T.V., Fiset, P., Varin, F. Anesth. Analg. (1998) [Pubmed]
  20. The pharmacoeconomics of neuromuscular blocking drugs: a perioperative cost-minimization strategy in children. Splinter, W.M., Isaac, L.A. Anesth. Analg. (2001) [Pubmed]
  21. The clinical neuromuscular pharmacology of cisatracurium versus vecuronium during outpatient anesthesia. Stevens, J.B., Walker, S.C., Fontenot, J.P. Anesth. Analg. (1997) [Pubmed]
  22. Prolonged weakness after cisatracurium infusion: a case report. Davis, N.A., Rodgers, J.E., Gonzalez, E.R., Fowler, A.A. Crit. Care Med. (1998) [Pubmed]
  23. Comparison of the infusion requirements and recovery profiles of vecuronium and cisatracurium 51W89 in intensive care unit patients. Prielipp, R.C., Coursin, D.B., Scuderi, P.E., Bowton, D.L., Ford, S.R., Cardenas, V.J., Vender, J., Howard, D., Casale, E.J., Murray, M.J. Anesth. Analg. (1995) [Pubmed]
  24. Dose requirements of infusions of cisatracurium or rocuronium during hypothermic cardiopulmonary bypass. Cammu, G., Coddens, J., Hendrickx, J., Deloof, T. British journal of anaesthesia. (2000) [Pubmed]
  25. HPLC determination of cisatracurium besylate and propofol mixtures with LC-MS identification of degradation products. Zhang, H., Wang, P., Bartlett, M.G., Stewart, J.T. Journal of pharmaceutical and biomedical analysis. (1998) [Pubmed]
  26. Response to cisatracurium in patient with Charcot-Marie-Tooth disease. García-Ferreira, J., Hernández-Palazón, J. European journal of anaesthesiology. (2005) [Pubmed]
  27. Central command and the cutaneous vascular response to isometric exercise in heated humans. Shibasaki, M., Secher, N.H., Johnson, J.M., Crandall, C.G. J. Physiol. (Lond.) (2005) [Pubmed]
  28. Cisatracurium pharmacodynamics in patients with oculopharyngeal muscular dystrophy. Caron, M.J., Girard, F., Girard, D.C., Boudreault, D., Brais, B., Nassif, E., Chouinard, P., Ruel, M., Duranceau, A. Anesth. Analg. (2005) [Pubmed]
  29. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. De Wolf, A.M., Freeman, J.A., Scott, V.L., Tullock, W., Smith, D.A., Kisor, D.F., Kerls, S., Cook, D.R. British journal of anaesthesia. (1996) [Pubmed]
 
WikiGenes - Universities